Chuyi Ma1, Miaoran Lin1, Jiahui Gao1, Shurui Xu1, Li Huang1, Jingfang Zhu1, Jia Huang1, Jing Tao1, Lidian Chen2. 1. College of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China. 2. National-Local Joint Engineering Research Center of Rehabilitation Medicine Technology & Traditional Chinese Medicine Rehabilitation Research Center of State Administration of Traditional Chinese Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China. cld@fjtcm.edu.cn.
Abstract
BACKGROUND: Accumulated evidence has proved that both neuroinflammation and neuroprotection existing at the stage of mild cognitive impairment (MCI) may mediate its progression, which can conversely be modulated by physical activity (PA). However, further research is needed to clarify which factors are involved in that process. OBJECTIVES: To identify the impact of PA on inflammatory cytokines and neuroprotective factors in individuals with MCI. METHODS: Four databases [PubMed, Cochrane Library, Cochrane Library (Trials), Embase and Web of Science Core Collection] were searched from their inception to October 2021 for randomized-controlled trials (RCTs) assessing the biochemical effect of PA on biomarkers in participants with MCI. Pooled effect size was calculated by the standardized mean difference (SMD). RESULTS: A total of 13 RCTs involving 514 participants by reporting 8 inflammatory cytokines [tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, -6, -8, -10, -15, C-reactive protein (CRP) and interferon-γ (IFN-γ) and 5 neuroprotective factors (brain-derived neurotrophic factor (BDNF), insulin-like growth factor (IGF-1), vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), irisin] were included. The meta-analysis showed that PA had positive effects on decreasing TNF-α (SMD = - 0.32, 95% CI - 0.58 to 0.07, p = 0.01; I2 = 32%) and CRP (SMD = - 0.68, 95% CI - 1.05 to 0.32, p = 0.0002; I2 = 18%), while significantly improving BDNF (SMD = 0.32, 95% CI 0.09-0.56, p = 0.007; I2 = 42%) and IGF-1 (SMD = 0.42, 95% CI 0.03-0.81, p = 0.03; I2 = 0%). CONCLUSION: PA had a certain effect on inhibiting inflammatory cytokines but promoting neuroprotective factors in individuals with MCI which may provide a possible explanation for the potential molecular mechanism of PA on cognitive improvement.
BACKGROUND: Accumulated evidence has proved that both neuroinflammation and neuroprotection existing at the stage of mild cognitive impairment (MCI) may mediate its progression, which can conversely be modulated by physical activity (PA). However, further research is needed to clarify which factors are involved in that process. OBJECTIVES: To identify the impact of PA on inflammatory cytokines and neuroprotective factors in individuals with MCI. METHODS: Four databases [PubMed, Cochrane Library, Cochrane Library (Trials), Embase and Web of Science Core Collection] were searched from their inception to October 2021 for randomized-controlled trials (RCTs) assessing the biochemical effect of PA on biomarkers in participants with MCI. Pooled effect size was calculated by the standardized mean difference (SMD). RESULTS: A total of 13 RCTs involving 514 participants by reporting 8 inflammatory cytokines [tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, -6, -8, -10, -15, C-reactive protein (CRP) and interferon-γ (IFN-γ) and 5 neuroprotective factors (brain-derived neurotrophic factor (BDNF), insulin-like growth factor (IGF-1), vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), irisin] were included. The meta-analysis showed that PA had positive effects on decreasing TNF-α (SMD = - 0.32, 95% CI - 0.58 to 0.07, p = 0.01; I2 = 32%) and CRP (SMD = - 0.68, 95% CI - 1.05 to 0.32, p = 0.0002; I2 = 18%), while significantly improving BDNF (SMD = 0.32, 95% CI 0.09-0.56, p = 0.007; I2 = 42%) and IGF-1 (SMD = 0.42, 95% CI 0.03-0.81, p = 0.03; I2 = 0%). CONCLUSION: PA had a certain effect on inhibiting inflammatory cytokines but promoting neuroprotective factors in individuals with MCI which may provide a possible explanation for the potential molecular mechanism of PA on cognitive improvement.
Authors: Eva Bagyinszky; Vo Van Giau; Kyuhwan Shim; Kyoungho Suk; Seong Soo A An; SangYun Kim Journal: J Neurol Sci Date: 2017-03-22 Impact factor: 3.181
Authors: A Okello; P Edison; H A Archer; F E Turkheimer; J Kennedy; R Bullock; Z Walker; A Kennedy; N Fox; M Rossor; D J Brooks Journal: Neurology Date: 2009-01-06 Impact factor: 9.910
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566
Authors: Peter Parbo; Rola Ismail; Kim V Hansen; Ali Amidi; Frederik H Mårup; Hanne Gottrup; Hans Brændgaard; Bengt O Eriksson; Simon F Eskildsen; Torben E Lund; Anna Tietze; Paul Edison; Nicola Pavese; Morten G Stokholm; Per Borghammer; Rainer Hinz; Joel Aanerud; David J Brooks Journal: Brain Date: 2017-07-01 Impact factor: 13.501
Authors: Cindy K Barha; Ryan S Falck; John R Best; Lindsay S Nagamatsu; Ging-Yuek Robin Hsiung; A William Sheel; Chun Liang Hsu; Arthur F Kramer; Michelle W Voss; Kirk I Erickson; Jennifer C Davis; J Kevin Shoemaker; Lara Boyd; Rachel A Crockett; Lisanne Ten Brinke; Louis Bherer; Joel Singer; Liisa A M Galea; Claudia Jacova; Alexis Bullock; Sofia Grant; Teresa Liu-Ambrose Journal: Trials Date: 2022-09-09 Impact factor: 2.728